ICYMI: The Biosimilar "Buy In" In 2023, we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients. https://t.co/U7YTH0Uodf https://t.co/PZelN4G5Jb